Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

products.

Europe and Rest of the World ("ROW") Generic Sales

Sales of European and ROW generic products were $217 million in the second

quarter of 2008, compared to $188 million in the prior year period. This

increase is primarily related to the positive impact of foreign currency

exchange fluctuations compared to the prior year period. Excluding the

impact of foreign currency fluctuations, overall sales were in line with

last year as strong growth in Russia and other Central European markets

offset declines in Croatia and Germany.

Proprietary Product Sales

The Company's proprietary product sales were $118 million for the second quarter of 2008, compared to $102 million in the prior year period. For the first six months of 2008, proprietary product sales were $214 million, compared to $191 million in the prior year period. The increase in proprietary sales for the quarter and the six month period was primarily attributable to increased sales of several products, including SEASONIQUE(R) extended-cycle oral contraceptive and the PARAGARD(R) IUC.

Alliance and Development Revenue

During the second quarter of 2008, the Company reported alliance and development revenue of $93 million, up from $36 million in the prior year period. For the first six months of 2008, alliance and development revenue was $125 million, compared to $61 million in the prior year period. The increase in the quarter and the six month period is primarily related to the $53 million payment made by Allergan to Barr in May 2008 related to Allergan's buy-out of all future financial obligations related to the Sanctura(R) product that PLIVA divested in 2005 to Esprit Pharma, which has since been acquired by Allergan.

Other Revenue

Other revenue primarily includes revenue from the Company's non-core operations, including the diagnostic, disinfectants, dialysis and infusions (DDD&I) business. Other revenue totaled $11
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
(Date:7/28/2015)... , July 28, 2015  Faced with increasing ... are palliative rather than symptomatic, the global healthcare ... existing therapies capable of curing or significantly changing ... starting to look towards regenerative medicine as a ... new paradigm in human health with the potential ...
(Date:7/27/2015)... - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the ... the treatment of cancer, today provides the following financial ... a $1,000,000 unit offering private placement.  This financing is ... Company at a price of $0.06 per unit.  Each ... common share purchase warrant.  Each whole warrant is exercisable ...
(Date:7/27/2015)... ... July 27, 2015 , ... Brady ... a new video: 3 Ways to GHS Labels . This video provides ... Globally Harmonized System (GHS) by effectively labeling chemical containers. , “With the fourth ...
Breaking Biology Technology:Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 5Quest PharmaTech Closes $1,000,000 Private Placement 2Brady Releases “3 Roads to GHS Labels” Video 2
... NEW YORK, Sept. 8 Reportlinker.com announces that ... , , Small Molecule Kinase ... http://www.reportlinker.com/p0131227/Small-Molecule-Kinase-Inhibitors.html , , ... Inhibitors in Millions of US$ by the following Product Segments: ...
... , , , Dan ... PHILADELPHIA, Sept. 8 PriceSpective, a value strategy consultancy that ... pleased to announce that it has hired Dan Ross to open ... brings 9 years of experience working with healthcare companies in both ...
... , , ... (Nasdaq: PPHM ) today reported completion of patient enrollment ... and paclitaxel in advanced breast cancer patients. The trial,s planned ... undergoing treatment and follow-up. The primary objective of the multi-center, ...
Cached Biology Technology:Reportlinker Adds Small Molecule Kinase Inhibitors Report 2Reportlinker Adds Small Molecule Kinase Inhibitors Report 3Reportlinker Adds Small Molecule Kinase Inhibitors Report 4Reportlinker Adds Small Molecule Kinase Inhibitors Report 5Reportlinker Adds Small Molecule Kinase Inhibitors Report 6Reportlinker Adds Small Molecule Kinase Inhibitors Report 7Reportlinker Adds Small Molecule Kinase Inhibitors Report 8Reportlinker Adds Small Molecule Kinase Inhibitors Report 9Reportlinker Adds Small Molecule Kinase Inhibitors Report 10PriceSpective Continues Global Expansion With New San Diego Office 2Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 2Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 3Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 4Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program 5
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/188684 for BEHAVIORAL-DIRECTED ... another new convenient and secure method to make ... innovative payment methods, introduced with its groundbreaking voice-direct ...
(Date:7/9/2015)... , July 9, 2015  Synaptics ... developer of human interface solutions, today announced ... industry,s first fully hardware encapsulated fingerprint sensor ... authentication technology is literally off the grid, ... biometric matching within the fingerprint sensor to ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... The world,s most powerful neutron source should be built in ... At a meeting in Brussels last night (28 May), ... the European Spallation Source (ESS), with a further two voting ... be the world,s most advanced centre for materials research, enabling ...
... say they,ve made a big improvement in a new breed ... one that may be a valuable addition to the battle ... antibody attached to a nanowire that,s attached to an electrical ... binds to is present in the liquid, it will bind ...
... Animals can simplify the brain control of their limb ... that operates against a spring made of the almost ... and illustrated by striking photographs and high-speed video footage, ... , of the movements of the mouthparts of crabs ...
Cached Biology News:Sweden to host 1.3 billion Euro research center 2A quicker, cheaper SARS virus detector -- one easily customizable for other targets 2Resilin springs simplify the control of crustacean limb movements 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Assay Diluent 500 mls...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: